A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

RT @kylifesciences: "Gene expr predictor response to EGFR-targeted therapy stratifies PFS to cetuximab in KRAS WT CRC http://t.co/DPKkeeCwD…

"Gene expr predictor response to EGFR-targeted therapy stratifies PFS to cetuximab in KRAS WT CRC http://t.co/DPKkeeCwDn." @fastercures

"Gene expr predictor response EGFR-targeted Tx stratifies PFS to cetuximab in KRAS WT CRC http://t.co/DPKkeeCwDn." https://t.co/xaTCJDA9pI

@InSilicoMeds, see "...stratifies PFS to cetuximab in KRAS WT http://t.co/oYB5VsqS11" by @UK_COP's @epblack25. https://t.co/ZKs4HB5qYk

@recnac1, related, please see http://t.co/oYB5Vt04xF by @UK_COP's @epblack25; stratifies PFS in KRAS-wildtype CRC. @rkvl HT @scientre

@recnac1, related, please see http://t.co/oYB5Vt04xF by @UK_COP's @epblack25; stratifies PFS in KRAS-wildtype CRC. @rkvl HT @scientre

@carisls, http://t.co/tSyTX0HY0R by @UK_COP PI http://t.co/w5HGXIr4jJ.

@AppliedBio, see http://t.co/tSyTX0HY0R by @UK_COP PI http://t.co/LkkWILJavV. cc @epblack25

@Integragen, please see http://t.co/Y3RL5c1TRw by @UK_COP PI http://t.co/1u86xOcpIu. Related, http://t.co/itt149Itcz.

@Integragen, please see http://t.co/Y3RL5c1TRw by @UK_COP PI http://t.co/1u86xOcpIu. Related, http://t.co/itt149Itcz.

Interesting research from Dr. Penni Black. RT @steen1969 please see http://t.co/NbjJgbttuo Response to therapy in colorectal cancer.

@ExactSciences, please see http://t.co/itt149Itcz by @UK_COP PI. Response to therapy in colorectal cancer.

"Update on KRAS & NRAS mutations in colorectal cancer http://t.co/BsymPAQrPu" by @MaverickNY. @UK_COP PI http://t.co/itt149Itcz HT @scientre

@GeneDx, RE: "Introduces Genetic Test Panels for Colon Cancer http://t.co/T6Ahr6W77i" see @UK_COP PI's http://t.co/itt149Itcz.

@GeneDx, RE: "Introduces Genetic Test Panels for Colon Cancer http://t.co/T6Ahr6W77i" see @UK_COP PI's http://t.co/itt149Itcz.

RE: mCRC molecular profiling for Tx http://t.co/lbK8ZtZnFx, @carisls @OncLive, see @UK_COP PI's http://t.co/oYB5VsqS11. @QuestDX @LABCORP

@MaverickNY, @UK_COP PI http://t.co/rgtPfhY0UK; http://t.co/oYB5VsqS11 & http://t.co/MCY1Mgq26v. Looking at PI3K, too.

@htheaks10 @ClearityFnd, please see http://t.co/oYB5VsqS11 & http://t.co/MCY1Mgq26v by @UK_COP PI http://t.co/rgtPfhY0UK. EGFR response.

@htheaks10 @ClearityFnd, please see http://t.co/oYB5VsqS11 & http://t.co/MCY1Mgq26v by @UK_COP PI http://t.co/rgtPfhY0UK. EGFR response.

RE: "Companion Dx for Cancer Drugs... http://t.co/P9DD98oU by @cathyarnst, see @UK_COP PI http://t.co/SiJNofbk & http://t.co/LM4TUzBp. EGFR

RE: "Companion Dx for Cancer Drugs... http://t.co/P9DD98oU by @cathyarnst, see @UK_COP http://t.co/SiJNofbk & http://t.co/LM4TUzBp. EGFR

See @UK_COP PI http://t.co/CC1iJXZH, @carisls, RE: mCRC patients & anti-EGFR response. Works irrespective of KRAS. @GenomicApps

This [http://t.co/LM4TUzBp] looks at response of KRAS WT patients, @carisls. @UK_COP PI http://t.co/uklxuHJY. Thanks!

This [http://t.co/LM4TUzBp] looks at response of KRAS WT patients, @carisls. @UK_COP PI http://t.co/uklxuHJY. Thanks!

This [http://t.co/LM4TUzBp] looks at response of KRAS WT patients, @carisls. @UK_COP PI http://t.co/uklxuHJY. Thanks!

RE: Luke's "A Lonely Voice..," @baruch_harris; improve care/reduce EGFR cost http://t.co/LM4TUzBp in KRAS WT. @mamenama @UK_COP

RE: Luke's "A Lonley Voice..," @baruch_harris; improve care/reduce EGFR cost http://t.co/LM4TUzBp in KRAS WT. @mamenama @UK_COP

@mtmdphd, plz see http://t.co/SiJNofbk , http://t.co/1R0q95tD & http://t.co/LM4TUzBp by @UK_COP's http://t.co/uklxuHJY Thx! EGFR Erlotinib

@mtmdphd, please see http://t.co/SiJNofbk, http://t.co/1R0q95tD & http://t.co/LM4TUzBp by UK_COP PI http://t.co/uklxuHJY Thx! EGFR Erlotinib

@gautamkollu, please see http://t.co/LM4TUzBp by @UK_COP PI http://t.co/uklxuHJY. Erbitux. Thanks! cc @MichaelPellini

@carisls, related, you should check out http://t.co/TqI9hR5E by http://t.co/OtvuvGTb…. Thanks!

This [http://t.co/ecqCElrC ] is cool, @djestes. Related, see http://t.co/LM4TUzBp by http://t.co/uklxuHJY. Thanks!

Yo, @CompleGenInc @washbio; see http://t.co/LM4TUzBp http://t.co/uklxuHJY. Signature works irrespective of KRAS, both small molecules/mAbs.

RE: @QIAGEN KRAS test for Erbitux, @bradloncar; see @UK_COP PI http://t.co/uklxuHJY & http://t.co/LM4TUzBp. Works irrespective of KRAS.

@MichaelBolick & @BerwynClarke, RE: http://t.co/L4OeavOE, please see @UK_COP PI http://t.co/uklxuHJY & http://t.co/LM4TUzBp. Thanks!

See @UK_COP PI http://t.co/LM4Ys9Kz, @Personal_RX_WI & @MichaelPellini. Response in CRC & NSCLC. Thanks! @kyeshwant

RT @steen1969: RE "@cytomx Therapeutics Inc Seeks to... http://t.co/AoIAMcde" see @UK_COP PI http://t.co/Ma5hR3Jm @Affymetrix array predict response. #EGFR

RE "@cytomx Therapeutics Inc Seeks to... http://t.co/AoIAMcde" see @UK_COP PI http://t.co/Ma5hR3Jm @Affymetrix array predict response. #EGFR

"[EGFR] drugs don’t work for ~ 40% patients who have mutant forms of KRAS" by @ldtimmerman; see @UK_COP PI http://t.co/Ma5hR3Jm. @Affymetrix

@dbsable See @UK_COP PI http://t.co/uklC2hKS predict drug response in CRC http://t.co/Ma5hR3Jm; built on @Affymetrix arrays. @DivaBiotech

RT @steen1969: @shinfuse See my @UK_COP colleague http://t.co/uklC2hKS in this area; http://t.co/Ma5hR3Jm Thanks!

@AltheaDx RE EGFR gene copy number assessment predicts response to anti-EGFR therapy in CRC; see http://1.usa.gov/me6oQz